Paper Details

  1. Home
  2. Paper Details

Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma.

Author: BleeckerEugene R, FitzGeraldJ Mark, GoldmanMitchell, HirschIan, Menzies-GowAndrew, NewboldPaul, WechslerMichael E, WuYanping, ZangrilliJames G

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Benralizumab, an anti-eosinophilic monoclonal antibody, is effective in reducing exacerbations and improving lung function in patients with severe, uncontrolled asthma with eosinophilic inflammation. This analysis shows that baseline factors, such as oral corticosteroid use, nasal polyposis, and lung function, can influence the efficacy of benralizumab.
Paper Details　
Original Abstract of the Article :
Benralizumab is an anti-eosinophilic monoclonal antibody that reduces exacerbations and improves lung function for patients with severe, uncontrolled asthma with eosinophilic inflammation. We evaluated the impact of baseline factors on benralizumab efficacy for patients with severe asthma.This analy...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203407/

データ提供：米国国立医学図書館（NLM）

Benralizumab for Severe Asthma: Baseline Factors Impacting Efficacy

Severe asthma, a debilitating respiratory condition, is like a desert windstorm, constantly challenging individuals with persistent symptoms. This research investigates the effectiveness of benralizumab, a new treatment for severe asthma, and explores the impact of baseline patient factors on its efficacy.

The researchers analyzed data from two Phase III clinical trials, evaluating the effectiveness of benralizumab in reducing exacerbations and improving lung function in patients with severe, uncontrolled asthma. They found that benralizumab was particularly effective in patients with higher baseline eosinophil counts and those who were using oral corticosteroids, suggesting that baseline factors can influence treatment response. It’s like understanding the desert terrain – knowing which oases are most likely to offer respite and nourishment.

Navigating the Desert of Asthma: Identifying Factors for Effective Treatment

This research provides valuable insights into the effectiveness of benralizumab for severe asthma. It highlights the importance of considering baseline patient factors to optimize treatment outcomes. It’s like understanding the desert landscape, recognizing the unique characteristics of each oasis and selecting the best route for a successful journey.

Finding the Right Oasis: Personalized Treatment for Severe Asthma

This research emphasizes the need for a personalized approach to treating severe asthma, taking into account individual patient characteristics. It’s like navigating the desert, choosing the appropriate oasis based on the specific needs and resources of each traveler. By understanding the factors that influence treatment response, we can improve patient outcomes and provide more effective care for those suffering from severe asthma.

Dr. Camel's Conclusion

This research adds valuable knowledge to the desert of asthma research. It underscores the importance of considering individual patient factors to optimize treatment outcomes for severe asthma. Just like a wise desert traveler selects the best oasis for their needs, understanding the interplay of factors can lead to more effective treatment strategies.

Date :
  1. Date Completed 2019-08-19
  2. Date Revised 2022-04-25
Further Info :

Pubmed ID

30139780

DOI: Digital Object Identifier

PMC6203407

Related Literature

Article Analysis
・Effects of benralizumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.